Filing Analysis
Asset Disposition
Filed Mar 31, 2026
MEDIUM
Oramed Pharmaceuticals completed the sale of its subsidiary Oratech Pharma to Lifeward Ltd. in exchange for equity, warrants, and a revenue-sharing agreement. Simultaneously, Oramed invested $9 million into Lifeward through senior secured convertible notes.
Red Flags
- The revenue-sharing agreement terminates if Lifeward's market capitalization reaches $200 million, potentially capping the upside of the disposition.
- Concentration risk: Oramed is heavily tying its value to the performance and equity of Lifeward Ltd.
Key Facts
- The transaction closed on March 25, 2026.
- Oramed sold 100% of Oratech Pharma, Inc. to Lifeward Ltd.
- Consideration included 1,250,363 Lifeward Ordinary Shares and 1,006,113 pre-funded warrants, representing up to 49.99% of Lifeward's fully diluted equity.
- Oramed will receive 4% revenue sharing on Lifeward's ReWalk Personal Exoskeleton products, capped by time (10 years) or a $200M market cap trigger.
- Oramed purchased $9,000,000 in senior secured convertible notes from Lifeward with a conversion price of $5.40 per share.
- Oramed received additional warrants to purchase 1,296,296 shares and 1,666,666 shares at $5.40 per share.
Material Agreement
Filed Feb 20, 2026
MEDIUM
Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company on February 19, 2026, receiving warrants to purchase 100,000 shares of Scilex common stock at $20.00/share in exchange for deferring an amortization payment on Scilex's Tranche B Notes. The deferred payment was subsequently made in November 2025, and the warrants expire December 13, 2029.
Red Flags
- Oramed's ongoing financial entanglement with Scilex, which has faced significant financial difficulties — the need for warrant compensation to defer a scheduled debt payment suggests Scilex liquidity stress
- The exercise price of $20.00/share with an anti-dilution floor of $8.22 suggests market expectation of potential Scilex dilution events
- The amortization payment originally due October 2025 was deferred and not paid until November 2025, indicating Scilex payment difficulties
- Cashless exercise fallback provision suggests uncertainty about Scilex's ability to maintain effective registration statements
- Related-party complexity: Oramed holds Senior Secured Convertible Notes in Scilex and now warrants, creating layered exposure to Scilex credit risk
Key Facts
- Oramed received warrants to purchase 100,000 shares of Scilex (SCLX) common stock at $20.00/share exercise price
- Warrants issued in exchange for Oramed deferring an October 1, 2025 amortization payment under Scilex's Senior Secured Convertible Note (Tranche B Notes)
- The deferred amortization payment was made to Oramed in November 2025
- Warrants are immediately exercisable upon issuance with expiration date of December 13, 2029
- Exercise price has anti-dilution protection with a floor price of $8.22
- Beneficial ownership cap of 4.99% (adjustable up to 9.99% with 61 days notice)
- Scilex must file an S-3 (or S-1) registration statement by the later of 30 days post-agreement, 10 days after Scilex's 10-K filing, or March 31, 2026
- Cashless exercise permitted if no effective registration statement exists at time of exercise
- Change-of-control provision entitles Oramed to Black-Scholes value repurchase in cash
- Original Securities Purchase Agreement with Scilex dated October 7, 2024
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.